Nautilus Biotechnology In...

0.77
-0.12 (-13.69%)
At close: Apr 03, 2025, 3:59 PM
0.79
1.87%
After-hours: Apr 03, 2025, 07:13 PM EDT

Company Description

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome.

It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.

The company was founded in 2016 and is headquartered in Seattle, Washington.

Nautilus Biotechnology Inc.
Nautilus Biotechnology Inc. logo
Country United States
IPO Date Aug 7, 2020
Industry Biotechnology
Sector Healthcare
Employees 155
CEO Sujal M. Patel

Contact Details

Address:
2701 Eastlake Avenue East
Seattle, Washington
United States
Website https://www.nautilus.bio

Stock Details

Ticker Symbol NAUT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001808805
CUSIP Number 63909J108
ISIN Number US63909J1088
Employer ID 00-0000000
SIC Code 3826

Key Executives

Name Position
Sujal M. Patel Co-Founder, Chief Executive Officer, President, Secretary & Director
Anna Mowry Chief Financial Officer & Treasurer
Gwen E. Weld Chief People Officer
Kentaro Suzuki Chief Marketing Officer
Chris Blessington Vice President of Corporate Marketing & Communications
Dr. Parag Mallick Ph.D. Co-Founder, Chief Scientist & Director
Dr. Subra Sankar Ph.D. Senior Vice President of Product Development
Matthew B. Murphy ESQ. General Counsel
Nick A. Nelson Chief Business Officer & Senior Vice President of Business Development

Latest SEC Filings

Date Type Title
Mar 21, 2025 4 Filing
Mar 05, 2025 SCHEDULE 13D/A [Amend] Filing
Mar 05, 2025 SCHEDULE 13D/A [Amend] Filing
Mar 04, 2025 4 Filing
Mar 04, 2025 4 Filing
Mar 04, 2025 4 Filing
Mar 04, 2025 4 Filing
Mar 04, 2025 4 Filing
Mar 04, 2025 4 Filing
Mar 04, 2025 4 Filing